Protease inhibitor therapy for hepatitis C virus-infection

Expert Opinion on Pharmacotherapy

Volumn 19, Issue 6, 2018, Pages 577-587

  de Leuw, P ^a   Stephan, C ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Direct acting antiviral; hepatitis C; HIV; NS3 4A protease inhibitor

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; GLECAPREVIR; GRAZOPREVIR; HEPACIVIRIN; HEPACIVIRIN INHIBITOR; PARITAPREVIR; PROTEINASE INHIBITOR; SIMEPREVIR; VOXILAPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NONHUMAN; PROTEINASE INHIBITION; REVIEW; DRUG EFFECT; HEPACIVIRUS;

HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS;

EID: 85044838784     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2018.1454428     Document Type: Review

References (101)

1. Global report on access to hepatitis C treatment. Focus on overcoming barriers. Geneva: WHO; 2016 [cited 2018 Feb22]. Available from: http://apps.who.int/iris/bitstream/10665/250625/1/WHO-HIV-2016.20-eng.pdf?ua≡1
2. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: WHO; 2014 [cited 2018 Feb22]. Available from: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1
3. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908–914.
4. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.
5. Orland JR, Wright TL, Cooper S., Acute hepatitis C. Hepatology. 2001;33:321–327.
6. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.
7. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844.
8. Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2:347–353.
9. Alter MJ., Epidemiology of viral hepatitis and hiv co-infection. J Hepatol. 2006;44:S6–S9.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965.
11. McHutchison JG, Lawitz EJ,; IDEAL Study Team, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Eng J Med. 2009;361:580–593.
12. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75–90.
13. Coilly A, Dumortier J, Botta-Fridlund D, et al. Multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future? PLoS One. 2015;10:e0138091.
14. Rockstroh JK, Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? [cited 2018 Feb22]. Available from: http://www.natap.org/2015/AASLD/AASLD_165.htm
15. McCauley JA, Rudd MT. Hepatitis C virus NS3/4a protease inhibitors. Curr Opin Pharmacol. 2016;30:84–92.
16. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
17. Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: impplications for diagnosis, development and control of viral diseases. Hepatology. 1991;14:381–388.
18. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791–796.
19. Catanese MT, Uryu K, Kopp M, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci. 2013;110:9505–9510.
20. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453–463.
21. Grakoui A, McCourt DW, Wychowski C, et al. Characterization of the hepatitis C virus-encoded serin proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol. 1993;67:2832–2843.
22. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
23. Mo H, Hedskog C, Lawitz E, et al. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017;140:151–157.
24. Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10–16.
25. Bae A, Sun SC, Qi X, et al. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010;54:5288–5297.
26. De Meyer S, Ghys A, Foster GR, et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat. 2013;20:395–403.
27. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544–1553.
28. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769–1778.
29. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5. Antivir Ther. 2011;16:1093–1102.
30. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009;49:1069–1082.
31. Dietz J, Susser S, Berkowski C, et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One. 2015;10:e0134395.
32. Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015;62:1008–1014.
33. Palanisamy N, Danielsson A, Kokkula C, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99:12–17.
34. Howe JA, Long J, Black S, et al. Clinical Implications of detectable baseline hepatitis C virus-genotype 1 NS3/4A-protease variants on the efficacy of boceprevir combined with peginterferon/ribavirin. Open Forum Infect Dis. 2014;1:1–7.
35. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948–956.
36. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148:e351.
37. Lawitz E, Yang JC, Stamm LM, et al. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3202. [Epub ahead of print].
38. Full Prescribing Information for Olyiso™. Washington (DC): FDA; 2013 [cited 2018 Feb22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf
39. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58:445–451.
40. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202,a phase IIa, open-label study. J Hepatol. 2012;56:1247–1253.
41. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
42. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-infected patients without cirrhosis: OPTIMIST-1, a Phase 3, randomized study. Hepatology. 2016;64:370–380.
43. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360–369.
44. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387–5396.
45. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
46. Full Prescribing Information for VIEKIRA PAK™. Washington (DC): FDA; 2014 [cited 2018 Feb22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf
47. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
48. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
49. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
50. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301–307.
51. Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017;2:494–500.
52. Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129.
53. Asselah T, Hezode C, Qaqish RB, et al. High SVR rates in patients with genotype 4 chronic hepatitis C infection and compensated cirrhosis with ombitasvir/paritaprevir/ritonavir co-administered with ribavirin (AGATE-I). J Hepatol. 2016;64:S827.
54. Krishnan P, Tripathi R, Schnell G, et al. Pooledanalysis of resistance in patients treated with ombitasvir/ABT-450/r anddasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology. 2014;60:1134a–35a.
55. Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–5454.
56. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62:S220.
57. Full Prescribing Information for ZEPATIER™. Washington (DC): FDA; 2016 [cited 2018 Feb22]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf
58. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161–4167.
59. Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59:1657–1665.
60. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913–921.
61. Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–997.
62. Pasquinelli C, McPhee F, Eley T, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012;56:1838–1844.
63. Petry AS, Fraser IP, O’Mara E, et al. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology. 2011;54:531a.
64. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62:32–36.
65. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564–572.
66. Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today (Barc). 2016;52:377–385.
67. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomized, open-label phase 2trial. Lancet. 2015;385:1075–1086.
68. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir(MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection(C-WORTHY): arandomised, open-label phase 2 trial. Lancet. 2015;385:1087–1097.
69. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
70. Kwo P, Gane E, Peng C-Y, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. J Hepatol. 2015;62:S674.
71. Zeuzem S, Ghalib R, Reddy KR, et al. The phase 3 C-EDGE treatment-naive (TN) study of a 12-weeek oral regimen of grazoprevir (GZR, MK-5172)/elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4 or 6 infection. J Hepatol. 2015;62:S213.
72. Wyles D, Wedemeyer H, Ben-Ari Z, et al. Grazoprevir, ruzasvir, and uprifosbuvir for HCV after NS5A treatment failure. Hepatology. 2017 Jul 7. DOI:10.1002/hep.29358
73. Lawitz EJ, O’Riordan WD, Asatryan A, et al. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for Hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother. 2015;60:1546–1555.
74. Ng T, Pilot-Matias T, Tripathi R, et al. Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. J Hepatol. 2016;64:S409–410.
75. Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV Genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151:651–659.
76. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–369.
77. Poordad F, Pol S, Asatryan S, et al. Magellan-1, Part 2: glecaprevir/pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Amsterdam: EASL; 2017.
78. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–1455.
79. Taylor J, Appleby T, Barauskas O, et al. P0899: preclinical profile of the pangenotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol. 2015;62:S681.
80. Rodriguez-Torres M, Glass S, Hill J, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016;23:614–622.
81. Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–2146.
82. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
83. Puoti M, Moioli MC, Travi G, et al. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis. 2012;32:103–113.
84. Lo Re V, Tate J, Kallan M, et al. Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCV-mono-infected patients despite combination antiretroviral therapy. IAC. Washington; 2012. WEAB0102 - Oral Abstract.
85. HCV GUIDIANCE. Recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA [Internet]; 2017 Sep 21 [cited 2018 Feb22]. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_September_21_2017_g.pdf[Last.
86. Arends JE, Lieveld FI, Boeijen LL, et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254–1262.
87. HEP Drug Interaction Checker. University of Liverpool [Internet]; 2018 [cited 2018 Feb23]. Available from: https://www.hep-druginteractions.org/
88. Neukam K, Morano-Amado LE, Rivero-Juárez A, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017;18:126–134.
89. Bischoff J, Mauss S, Cordes C, et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med. 2018. DOI:10.1111/hiv.12579
90. Deterding K, Spinner C, Schott E, et al. Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study. J Hepatol. 2016;64:S211.
91. Tyson GL, Prevalence and determinants of hepatitis B co-infection among a United States Veterans Administration cohort with hepatitis C. Texas Medical Center Dissertations (via ProQuest). AAI1515610. 2012.
92. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic Hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166:792–798.
93. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66:13–26.
94. Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology. 2017;pii: S0016-5085(17)36369–2. [Epub ahead of print]. DOI:10.1053/j.gastro.2017.11.011
95. Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27–36.
96. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
97. Kattakuzhy S, Levy R, Rosenthal E, et al. Hepatitis C genotype 3 disease. Hepatol Int. 2016;10:861–870.
98. Soumana DI, Kurt Yilmaz N, Ali A, et al. Molecular and dynamic mechanism underlying drug resistance in genotype 3 Hepatitis C NS3/4A protease. J Am Chem Soc. 2016;138:11850–11859.
99. Cohn J, Roberts T, Amorosa V, et al. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS. 2015;10:369.
100. Iyengar S, Tay-Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13:e1002032.
101. Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58:928–936.